滚动资讯
CellMitochondrial control of glycerolipid synthesis by a PEP shuttleCellFunctional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposonsCellDeep-learning-based <em>de novo</em> discovery and design of therapeutics that reverse disease-associated transcriptional phenotypesCellFour centuries of commercial whaling eroded 11,000 years of population stability in bowhead whalesFierceBiotechBeyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndromeEndpoints NewsLawmakers signal willingness to counter China’s biotech gainsEndpoints NewsSanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing caseEndpoints NewsFDA opens door to RMAT designations for therapies on clinical holdEndpoints NewsFDA seeks to encourage fewer animal studies with new draft guidanceBioPharma DiveRBC: Revolution, Xenon, Arrowhead among top takeover targetsBioPharma DiveJ&J wins FDA nod for psoriasis pill that aims to compete with top-selling injectionsFierceBiotechJenaValve的Trilogy瓣膜获得FDA首个主动脉反流适应症批准。
BioPharma Dive 2026年1月30日

阿斯利康深化肥胖症领域布局，与中国石药集团达成广泛合作。

阿斯利康深化肥胖症领域布局，与中国石药集团达成广泛合作。

原文
暂时没有全文，请查看原始来源。

目录

59 全部